Blueprint Medicines Corporation Stock Price and Value Analysis

Should you buy Blueprint Medicines Corporation stock? (NasdaqGS:BPMC). Let's see how it does in our automated value investing analysis system.

  • This company is not making money.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the BPMC Numbers

BPMC Price
(Blueprint Medicines Corporation stock price per share)
[?] PE Ratio versus Sector 60% lower than other Healthcare stocks
[?] PE Ratio versus Industry 86% lower than other Biotechnology stocks
[?] Free Cash Flow Jitter 324%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 4,087,352 shares shorted. With 59,193,441 shares available for purchase and an average trading volume over the past 10 trading days of 552,630, it would take at least 7.396 days for all of the short holders to cover their shorts.

Is Blueprint Medicines Corporation Stock on Sale?

Based on our analysis, we believe that you should not buy Blueprint Medicines Corporation right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy BPMC Stock?

Does Blueprint Medicines Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.